Secular Trends in the Management of Pediatric Graves’ Disease: A 25-Year Cohort
Authors' conclusion
Over 25 years, pediatric GD management evolved toward lower dose, prolonged MMI therapy with a marked decline in definitive treatment. These secular changes were not associated with worsening remission or relapse rates
Study context
- Population
- Children diagnosed with Graves' disease (GD) between 1999 and 2024 at a tertiary center; 79.7% female, median age 13.8 years (IQR 10.0–15.6)median follow-up 6.0 years
- Participants
- 128 children
- Exposure
- Calendar periods 1999–2024
- Outcome
- Secular trends in management of pediatric GD
Methodological detailssingle-centre, tertiary center
- Single-centre
- Tertiary center
Main finding
As reported in the abstract
- Initial management shifted exclusively to MMI, with discontinuation of propylthiouracil after 2009
- p < 0.001
- Median initial MMI dose, 1999-2004 vs 2015-2020
- 30 mg/day to 10 mg/day (p < 0.001 for the trend)
- Weight-adjusted MMI dose
- 0.59 to 0.32 mg/kg/day (p < 0.001 for trend)
- Use of RAI, 1999-2004 vs 2020-2024
- 55.6% to 9.8% (p < 0.001 for trend)
Observational data: associations, not effects.
Further findings
- Lower FT4 levels at diagnosis marginally associated with remission
- B = 0.41, SE = 0.22, p = 0.06
Safety
- MMI-related AEs
- 20.3% of patients
- Severe events
- 1.6%
Original publication
Secular Trends in the Management of Pediatric Graves’ Disease: A 25-Year Cohort. Horm Res Paediatr. Published 19 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →